

inert polystyrene and di-vinyl benzene coated with soluble -COOH groups. Accordingly, the particle is labeled with both a magnetic and fluorescent marker. This dual labeling permits monitoring of the molecule on multiple spatial scales, from intracellular distribution to distribution throughout the animal.

Methods for Detecting Cancer Cells

Thomas Ried, Evelin Schrock, Bijan M. Ghadimi (NHGRI). U.S. Provisional Application No. 60/127,637 filed 01 Apr 1999 (DHHS Reference No. E-211-1998/0-US-01); PCT Application No. PCT/US00/08588 filed 31 Mar 2000 (DHHS Reference No. E-211-1998/0-PCT-02); U.S. Patent Application No. 09/937,864 filed 31 Dec 2000 (DHHS Reference No. E-211-1998/0-US-03). *Licensing Contact*: Michael Ambrose; (301) 594-6565; ambrosem@mail.nih.gov.

The present application describes a highly sensitive assay for distinguishing between cancer and non-cancer epithelial cells in the blood. It provides an improved diagnostic technique for detecting cancer and determining the organ-origin of the cancer. This assay can be used to prove the neoplastic nature of cells and predict when shed tumor cells have or will become metastatic. A major advantage of the present invention is that tumor cells can also be recovered as viable cells. Thus, the tumor cells can be kept alive in vitro for a sufficient period of time to determine the effect of particular anti-tumor pharmaceuticals on the cells. Furthermore, the assay provides an early detector of treatment success or failure and thereby allows a treatment regimen to be customized for an individual patient with advanced primary cancer.

Method for Detecting Transmissible Spongiform Encephalopathies

Gary E. Hsich, Kimbra Kenney, Clarence J. Gibbs, Michael G. Harrington (NINDS). U.S. Patent 5,998,149 issued on 07 Dec 1999 (DHHS Reference No. E-055-1996/0-US-01); U.S. Patent 6,406,860 issued on 18 Jul 2002 (DHHS Reference No. E-055-1996/0-US-02). *Licensing Contact*: Michael Ambrose; (301) 594-6565; ambrosem@mail.nih.gov.

Improved assays for the detection of transmissible spongiform encephalopathies (TSEs) in humans and non-human mammals have been developed. The assays involve detecting the presence or absence of 14-3-3 proteins in cerebrospinal fluid. Elevated levels of these proteins are indicative of TSEs, in particular Creutzfeldt-Jacob disease in humans and animals with these diseases. This invention is

available for licensing on a non-exclusive basis.

Dated: December 1, 2003.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 03-30498 Filed 12-8-03; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel, Steroid Receptor Chaperones in Axonal Elongation.

Date: December 11, 2003.

Time: 8:30 am to 9:30 am.

Agenda: To review and evaluate grant applications.

Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202, (Telephone Conference Call).

Contact Person: W. Ernest Lyons, PhD, Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892-9529, (301) 496-4056.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel, Molecular Regulation of Neural Migration.

Date: December 11, 2003.

Time: 10 am to 3:30 pm.

Agenda: To review and evaluate grant applications.

Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202.

Contact Person: W. Ernest Lyons, PhD, Scientific Review Administrator, Scientific

Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892-9529, (301) 496-4056.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel, Program in Cognitive Neuroscience.

Date: December 18, 2003.

Time: 1 pm to 2:30 pm.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Richard D. Crosland, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892-9529, 301-594-0635.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel, NeuroAIDS Imaging Studies.

Date: January 8, 2004.

Time: 8 am to 5 pm.

Agenda: To review and evaluate grant applications.

Place: The Fairmont Washington, DC, 2401 M Street, NW, Washington, DC 20037.

Contact Person: Andrea Sawczuk, DDS, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS, 6001 Executive Boulevard, Room #3208, Bethesda, MD 20892, (301) 496-0660, sawczuka@ninds.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: December 4, 2003.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03-30494 Filed 12-8-03; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4630-FA-11B]

Announcement of Funding Award—FY 2001 Healthy Homes Grant Program

AGENCY: Office of the Secretary—Office of Healthy Homes Research Grant Program.

ACTION: Announcement of funding awards.

SUMMARY: In accordance with Section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this announcement notifies the public of additional funding decisions made by the Department in a competition for funding under the Healthy Homes Demonstration and Education Notice of Funding Availability (NOFA). This announcement contains the name and address of the award recipient and the amount of award.

FOR FURTHER INFORMATION CONTACT: Ellen R. Taylor, Department of Housing and Urban Development, Office of Healthy Homes and Lead Hazard

Control, Room P3206, 451 Seventh Street, SW., Washington, DC, 20410–3000, telephone (202) 755–1785, ext. 116. Hearing- and speech-impaired persons may access the number above via TTY by calling the toll free Federal Information Relay Service at 1–800–877–8339.

SUPPLEMENTARY INFORMATION: The authority for Healthy Homes Demonstration and Education Program is sections 501 and 502 of the Housing and Urban Development Act of 1970 and the Departments of Veterans Affairs and Housing and Urban Development, and Independent Agencies Appropriations Act, 2001, Pub. L. 106–377, approved October 27, 2000.

These awards were the result of a competition announced in a **Federal**

Register NOFA published on February 26, 2001 (66 FR 11893). The purpose of the competition was to award grant funding of approximately \$1,500,000 for grants and cooperative agreements for the Healthy Homes Research Program. Applications were scored and selected on the basis of selection criteria contained in that Notice.

The Catalog of Federal Domestic Assistance number for this program is 14.900.

A total of \$2,239,196 was awarded to six grantees. In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989 (103 Stat. 1987, 42 U.S.C. 3545), the Department is publishing the names, addresses, and amounts of this awards as follows:

Awardee	Address	Amount of grant
Air Quality Sciences, Inc.	1337 Capital Circle, Marietta, GA 30067	\$210,299.00
Columbia University	60 Haven Avenue, B–106, New York, NY 10032	505,365.00
Duke University	Box 90077, Durham, NC 27708–0077	405,217.00
Radiation Monitoring Devices, Inc.	44 Hunt Street, Watertown, MA 0272	449,444.00
Research Triangle Institute	3040 Cornwallis Road, Research Triangle Park, NC 27709	220,082.00
University of Cincinnati	PO Box 670056, Cincinnati, OH 45267–0056	448,789.00

Dated: November 4, 2003.

Joseph F. Smith,

Deputy Director, Office of Healthy Homes and Lead Hazard Control.

[FR Doc. 03–30412 Filed 12–8–03; 8:45 am]

BILLING CODE 4210–70–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4723–FA–30]

Announcement of Funding Award—FY 2002 Healthy Homes Demonstration, and Healthy Homes and Lead Technical Studies Grant Programs

AGENCY: Office of the Secretary—Office of Healthy Homes and Lead Hazard Control, HUD.

ACTION: Announcement of funding awards.

SUMMARY: In accordance with Section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this announcement notifies the public of funding decisions made by the Department in a competition for funding under the Healthy Homes Demonstration and Lead Technical Studies Notice of Funding

Availability (NOFA). This announcement contains the name and address of the award recipients and the amounts of award.

FOR FURTHER INFORMATION CONTACT: For the Healthy Homes Demonstration and Healthy Homes Technical Studies Grant Programs, Ellen R. Taylor, Department of Housing and Urban Development, Office of Healthy Homes and Lead Hazard Control, Room P3206, 451 Seventh Street SW., Washington, DC, 20410–3000, telephone (202) 755–1785, ext. 116. For the Lead Technical Studies Grant Program, Warren Friedman, at the same address, phone extension 159. Hearing- and speech-impaired persons may access the numbers above via TTY by calling the toll free Federal Information Relay Service at 1–800–877–8339.

SUPPLEMENTARY INFORMATION: The authority for the Healthy Homes Demonstration and Lead Technical Studies Program is sections 501 and 502 of the Housing and Urban Development Act of 1970 and the Departments of Veterans Affairs and Housing and Urban Development, and Independent Agencies Appropriations Act, 2002, Public Law 107–73, approved November 26, 2001.

These awards were the result of a competition announced in **Federal Register** NOFAs published on March 26, 2002 for Healthy Homes and Lead Technical Studies (67 FR 14093), and for Healthy Homes Demonstration (67 FR 14115). The purpose of the competition was to award grant funding of approximately \$8,600,000 for grants and cooperative agreements for the Healthy Homes Demonstration and the Healthy Homes Lead Technical Studies Grant Programs. Applications were scored and selected on the basis of selection criteria contained in those Notices.

A total of \$8,586,202 was awarded to 17 grantees. \$5,947,235 was awarded to 9 Healthy Homes Demonstration grantees, and \$2,638,967 was awarded to 8 Healthy Homes and Lead Technical Studies grantees.

The Catalog of Federal Domestic Assistance number for this program is 14.901.

In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989 (103 Stat. 1987, 42 U.S.C. 3545), the Department is publishing the names, addresses, and amounts of this awards as follows: